The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study.
 
Sophie Cousin
Honoraria - AstraZeneca; MSD Oncology; Sanofi; Takeda
Consulting or Advisory Role - Janssen Oncology
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Takeda
 
Carine Bellera
Consulting or Advisory Role - BMS
 
Jean Philippe Guégan
No Relationships to Disclose
 
Quentin Thomas
No Relationships to Disclose
 
Iphigenie Korakis
Honoraria - MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Anaveon (Inst); Astellas Pharma (Inst); C4 Therapeutics (Inst); DAIICHI Sankyo (Inst); Dragonfly Therapeutics (Inst); Fore Biotherapeutics (Inst); Gilead Sciences (Inst); ImCheck therapeutics (Inst); Immunocore (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - Roche
 
Jean-Philippe Metges
Honoraria - Amgen; Beigene; BeiGene; Gilead Sciences; MSD Oncology; Pierre Fabre; Pierre Fabre
Consulting or Advisory Role - Bayer; BeiGene; BeiGene; MSD Oncology
Travel, Accommodations, Expenses - BeiGene; MSD Oncology
 
Fanny Bouteiller
No Relationships to Disclose
 
Michèle Kind
No Relationships to Disclose
 
Laura Leroy
No Relationships to Disclose
 
Xavier Quantin
Honoraria - Amgen; AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BMS (Inst); BMS France (Inst); Daiich; Lilly; Sanofi (Inst)
Consulting or Advisory Role - Ipsen
Travel, Accommodations, Expenses - Daiichi; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; MSD Oncology; Pfizer; SANOFI
 
Isabelle Soubeyran
Research Funding - AstraZeneca (Inst)
 
Alban Bessede
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS